Phase 1, Double-Blinded, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Safety and Pharmacokinetics Trial of AVR-48
Latest Information Update: 08 Apr 2025
At a glance
- Drugs AVR 48 (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Adverse reactions
- Sponsors AyuVis Research
Most Recent Events
- 04 Mar 2025 New trial record